AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 30366945 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose radiation therapy (LDRT) - 1 Gray per fraction, administered six times in 2 weeks
Number of subjects: 55
Study 30366945 — intervention group
Group type: COMPARATOR
Intervention: Sham intervention
Number of subjects: 55
Study 30366945 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose radiation therapy (LDRT)
Number of subjects: 55
Study 30172088 — intervention group
Group type: EXPERIMENTAL
Intervention: Decompressive hemicraniectomy (DHC) without clot evacuation, n = 13
Number of subjects: 30
Study 30172088 — intervention group
Group type: COMPARATOR
Intervention: Craniotomy with clot evacuation, n = 17
Number of subjects: 30
Study 27841912 — intervention group
Group type: EXPERIMENTAL
Intervention: Phosphorylcholine-coated oxygenators
Number of subjects: 20
Study 27841912 — intervention group
Group type: COMPARATOR
Intervention: Uncoated oxygenators
Number of subjects: 20
Study 24568907 — intervention group
Group type: EXPERIMENTAL
Intervention: Huangqi injection (0.5 mL/kg·d for 35 days)
Number of subjects: 91
Study 24568907 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (control)
Number of subjects: 91
Study 22777368 — intervention group
Group type: EXPERIMENTAL
Intervention: Sacrospinous ligament fixation
Number of subjects: 163
Study 22777368 — intervention group
Group type: EXPERIMENTAL
Intervention: Uterosacral vault suspension with perioperative pelvic floor muscle training
Number of subjects: 163
Study 22777368 — intervention group
Group type: EXPERIMENTAL
Intervention: Uterosacral vault suspension without perioperative pelvic floor muscle training
Number of subjects: 163
Study 22777368 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 163
Study 20220529 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertraline 50 mg
Number of subjects: 99
Study 20220529 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 99
Study 17927635 — intervention group
Group type: EXPERIMENTAL
Intervention: VUS + CHX chip
Number of subjects: 20
Study 17927635 — intervention group
Group type: COMPARATOR
Intervention: VUS alone
Number of subjects: 20
Study 16054381 — intervention group
Group type: EXPERIMENTAL
Intervention: Protamine administered 5 min after cardiopulmonary bypass
Number of subjects: 30
Study 16054381 — intervention group
Group type: EXPERIMENTAL
Intervention: Protamine administered 35 min after cardiopulmonary bypass
Number of subjects: 30
Study 12107212 — intervention group
Group type: EXPERIMENTAL
Intervention: r-hCG (5000 IU, 250 microg)
Number of subjects: 40
Study 12107212 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 12107212 — intervention group
Group type: EXPERIMENTAL
Intervention: r-hCG
Number of subjects: 40
Study 10418923 — intervention group
Group type: EXPERIMENTAL
Intervention: Live attenuated human-bovine reassortant rotavirus vaccine (D x UK) - single oral dose (10^5.3 pfu)
Number of subjects: 55
Study 10418923 — intervention group
Group type: EXPERIMENTAL
Intervention: Live attenuated human-bovine reassortant rotavirus vaccine (DS-1 x UK) - single oral dose (10^5.8 pfu)
Number of subjects: 55
Study 10418923 — intervention group
Group type: EXPERIMENTAL
Intervention: Live attenuated human-bovine reassortant rotavirus vaccine (P x UK) - single oral dose (10^5.8 pfu)
Number of subjects: 55
Study 10418923 — intervention group
Group type: EXPERIMENTAL
Intervention: Live attenuated human-bovine reassortant rotavirus vaccine (ST3 x UK) - single oral dose (10^5.8 pfu)
Number of subjects: 55
Study 10418923 — intervention group
Group type: EXPERIMENTAL
Intervention: Live attenuated human-bovine reassortant rotavirus vaccine (D x UK) - two doses
Number of subjects: 55
Study 8562273 — intervention group
Group type: EXPERIMENTAL
Intervention: Antihypertensive therapy
Number of subjects: 0
Study 8562273 — intervention group
Group type: EXPERIMENTAL
Intervention: Antihypertensive treatment
Number of subjects: 0
Study 8562273 — intervention group
Group type: EXPERIMENTAL
Intervention: Antihypertensive agents
Number of subjects: 0
Study 2236756 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled formoterol (12 micrograms)
Number of subjects: 12
Study 2236756 — intervention group
Group type: COMPARATOR
Intervention: Inhaled salbutamol (200 micrograms)
Number of subjects: 12
Study 2236756 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 138664 — intervention group
Group type: EXPERIMENTAL
Intervention: Ferrous sulfate containing 60 mg elemental iron twice daily
Number of subjects: 310
Study 138664 — intervention group
Group type: EXPERIMENTAL
Intervention: Folic acid 5 mg twice daily
Number of subjects: 310
Study 138664 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of iron and folic acid
Number of subjects: 310
Study 138664 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 310
Study 30791702 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic songwriting intervention (12-session identity-targeted songwriting programme)
Number of subjects: 47
Study 30791702 — intervention group
Group type: COMPARATOR
Intervention: Care as usual (control group)
Number of subjects: 47
Study 26846145 — intervention group
Group type: EXPERIMENTAL
Intervention: Usual care plus an educational booklet at discharge with supportive telephone follow‐up on postoperative day 10
Number of subjects: 416
Study 26846145 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 416
Study 26338030 — intervention group
Group type: EXPERIMENTAL
Intervention: Associative learning task with color/shape stimuli
Number of subjects: 0
Study 26338030 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual search task with shape target and irrelevant color distractors
Number of subjects: 0
Study 26338030 — intervention group
Group type: EXPERIMENTAL
Intervention: Learning experience with predictive color stimuli
Number of subjects: 0
Study 26338030 — intervention group
Group type: EXPERIMENTAL
Intervention: Blocked tasks (Experiment 3)
Number of subjects: 0
Study 26338030 — intervention group
Group type: EXPERIMENTAL
Intervention: Tasks on two successive days (Experiment 4)
Number of subjects: 0
Study 24392555 — intervention group
Group type: EXPERIMENTAL
Intervention: Subconjunctival bevacizumab (2.5 mg/0.1 ml)
Number of subjects: 122
Study 24392555 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical bevacizumab (2.5%, 25 mg/ml)
Number of subjects: 122
Study 24392555 — intervention group
Group type: COMPARATOR
Intervention: Sham injection (Control Group B)
Number of subjects: 122
Study 22118442 — intervention group
Group type: EXPERIMENTAL
Intervention: R-ACVBP (rituximab, doxorubicin, cyclophosphamide, vindesine, bleomycin, and prednisone)
Number of subjects: 379
Study 22118442 — intervention group
Group type: COMPARATOR
Intervention: R-CHOP (rituximab, doxorubicin, cyclophosphamide, vincristine, and prednisone)
Number of subjects: 379
Study 18848413 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive dietary advice plus information on physical activity
Number of subjects: 30
Study 18848413 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive dietary advice
Number of subjects: 30
Study 18848413 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 30
Study 16532983 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical zipper technique
Number of subjects: 50
Study 16532983 — intervention group
Group type: COMPARATOR
Intervention: Conventional nylon suture
Number of subjects: 50
Study 14681633 — intervention group
Group type: EXPERIMENTAL
Intervention: Localized subcontractile electrical stimulation on the feet of ischemic limbs for three 60‐minute periods each day over a 6‐week period
Number of subjects: 36
Study 14681633 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 36
Study 11033396 — intervention group
Group type: EXPERIMENTAL
Intervention: Photorefractive keratectomy (PRK) for myopia correction
Number of subjects: 5936
Study 11033396 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct argon-green laser photocoagulation for CNV treatment
Number of subjects: 5936
Study 9183445 — intervention group
Group type: EXPERIMENTAL
Intervention: Protein Profile of Orientation (PPO)
Number of subjects: 76
Study 9183445 — intervention group
Group type: COMPARATOR
Intervention: Classical biological explorations
Number of subjects: 76
Study 8331618 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose insulin infusion (0.25 mU/kg/min)
Number of subjects: 0
Study 8331618 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose insulin infusion (1.0 mU/kg/min)
Number of subjects: 0
Study 8331618 — intervention group
Group type: EXPERIMENTAL
Intervention: Basal and insulin infusion periods
Number of subjects: 0
Study 3538109 — intervention group
Group type: EXPERIMENTAL
Intervention: Lithium alone
Number of subjects: 18
Study 3538109 — intervention group
Group type: EXPERIMENTAL
Intervention: Lithium and lecithin
Number of subjects: 18
Study 29754582 — intervention group
Group type: EXPERIMENTAL
Intervention: EC with nicotine
Number of subjects: 10
Study 29754582 — intervention group
Group type: COMPARATOR
Intervention: EC without nicotine
Number of subjects: 10
Study 28915827 — intervention group
Group type: EXPERIMENTAL
Intervention: Guided Walking Program, 6 months duration, 5 times a week, including supervised physical activity and educational sessions
Number of subjects: 148
Study 28915827 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 148
Study 28915827 — intervention group
Group type: EXPERIMENTAL
Intervention: Adoption data from health center team
Number of subjects: 148
Study 28915827 — intervention group
Group type: EXPERIMENTAL
Intervention: Qualitative data regarding program implementation
Number of subjects: 148
Study 26030192 — intervention group
Group type: EXPERIMENTAL
Intervention: Neuronox
Number of subjects: 196
Study 26030192 — intervention group
Group type: COMPARATOR
Intervention: BOTOX
Number of subjects: 196
Study 26030192 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 196
Study 24029556 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-sample OC-Auto® fecal immunochemical test (FIT)
Number of subjects: 2263
Study 24029556 — intervention group
Group type: EXPERIMENTAL
Intervention: 2-sample InSure® FIT
Number of subjects: 2263
Study 24029556 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-sample guaiac Hemoccult SENSA®
Number of subjects: 2263
Study 20880171 — intervention group
Group type: EXPERIMENTAL
Intervention: Lafutidine 10 mg administered twice daily for 14 days
Number of subjects: 16
Study 20880171 — intervention group
Group type: COMPARATOR
Intervention: Placebo administered twice daily for 14 days
Number of subjects: 16
Study 18248495 — intervention group
Group type: EXPERIMENTAL
Intervention: Tacrolimus 0.1% ointment
Number of subjects: 50
Study 18248495 — intervention group
Group type: COMPARATOR
Intervention: Topical corticosteroids (standard therapy)
Number of subjects: 50
Study 17176334 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher transfusion threshold (10 g per dL)
Number of subjects: 0
Study 17176334 — intervention group
Group type: COMPARATOR
Intervention: Lower transfusion threshold (7 g per dL)
Number of subjects: 0
Study 14678131 — intervention group
Group type: EXPERIMENTAL
Intervention: RVOT pacing
Number of subjects: 103
Study 14678131 — intervention group
Group type: COMPARATOR
Intervention: RVA pacing
Number of subjects: 103
Study 14678131 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual-site RV pacing
Number of subjects: 103
Study 10854006 — intervention group
Group type: EXPERIMENTAL
Intervention: Lacidipine (4‐6 mg od)
Number of subjects: 15
Study 10854006 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide (HCTZ) (25‐50 mg od)
Number of subjects: 15
Study 8935693 — intervention group
Group type: EXPERIMENTAL
Intervention: Felodipine-ER 5mg/day
Number of subjects: 121
Study 8935693 — intervention group
Group type: COMPARATOR
Intervention: Nifedipine-OROS 30mg/day
Number of subjects: 121
Study 8267872 — intervention group
Group type: EXPERIMENTAL
Intervention: 20% benzocaine
Number of subjects: 20
Study 8267872 — intervention group
Group type: COMPARATOR
Intervention: Placebo (80% polyethylene glycol)
Number of subjects: 20
Study 3885483 — intervention group
Group type: EXPERIMENTAL
Intervention: Leukocyte-depleted red cells (Group 2)
Number of subjects: 107
Study 3885483 — intervention group
Group type: COMPARATOR
Intervention: Packed red cells (Group 1)
Number of subjects: 107
Study 30904853 — intervention group
Group type: EXPERIMENTAL
Intervention: CPAP therapy
Number of subjects: 0
Study 30904853 — intervention group
Group type: COMPARATOR
Intervention: Conventional medical therapy
Number of subjects: 0
Study 29678523 — intervention group
Group type: EXPERIMENTAL
Intervention: Adipose tissue-derived mesenchymal stem cell (ASC) therapy
Number of subjects: 30
Study 29678523 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 27326859 — intervention group
Group type: EXPERIMENTAL
Intervention: Azithromycin-Chloroquine (AZCQ; 250 mg AZ/155 mg CQ base)
Number of subjects: 2891
Study 27326859 — intervention group
Group type: COMPARATOR
Intervention: Sulfadoxine-Pyrimethamine (SP; 1,500/75 mg SP QD for 1 day)
Number of subjects: 2891
Study 27326859 — intervention group
Group type: EXPERIMENTAL
Intervention: Azithromycin-Chloroquine (AZCQ)
Number of subjects: 2891
Study 27326859 — intervention group
Group type: COMPARATOR
Intervention: Sulfadoxine-Pyrimethamine (SP)
Number of subjects: 2891
Study 25065337 — intervention group
Group type: EXPERIMENTAL
Intervention: HF1 urinary proteomic classifier
Number of subjects: 745
Study 25065337 — intervention group
Group type: EXPERIMENTAL
Intervention: HF2 urinary proteomic classifier
Number of subjects: 745
Study 22763083 — intervention group
Group type: EXPERIMENTAL
Intervention: Total sleep deprivation
Number of subjects: 8
Study 22763083 — intervention group
Group type: COMPARATOR
Intervention: 7 hours of sleep at night
Number of subjects: 8
Study 20711566 — intervention group
Group type: EXPERIMENTAL
Intervention: Cued inphase BMT
Number of subjects: 0
Study 20711566 — intervention group
Group type: COMPARATOR
Intervention: Cued antiphase BMT
Number of subjects: 0
Study 20711566 — intervention group
Group type: COMPARATOR
Intervention: Repetitive unimanual movement training
Number of subjects: 0
Study 18588481 — intervention group
Group type: EXPERIMENTAL
Intervention: IC51 (inactivated Japanese encephalitis vaccine)
Number of subjects: 2675
Study 18588481 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2675
Study 16097223 — intervention group
Group type: EXPERIMENTAL
Intervention: Tooth tissue-borne expander (Haas-type)
Number of subjects: 8
Study 16097223 — intervention group
Group type: COMPARATOR
Intervention: Tooth-borne expander (Hyrax)
Number of subjects: 8
Study 16097223 — intervention group
Group type: COMPARATOR
Intervention: Both expanders (Haas-type and Hyrax)
Number of subjects: 8
Study 11817581 — intervention group
Group type: EXPERIMENTAL
Intervention: Tidal irrigation (TI)
Number of subjects: 180
Study 11817581 — intervention group
Group type: COMPARATOR
Intervention: Sham irrigation (SI)
Number of subjects: 180
Study 11092282 — intervention group
Group type: COMPARATOR
Intervention: NPH insulin therapy
Number of subjects: 79
Study 11092282 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultralente insulin therapy
Number of subjects: 79
Study 11092282 — intervention group
Group type: EXPERIMENTAL
Intervention: Both regimens
Number of subjects: 79
Study 9314730 — intervention group
Group type: EXPERIMENTAL
Intervention: Bimanual paradigm with varied shape and size of trajectories for two limbs
Number of subjects: 0
Study 8340194 — intervention group
Group type: EXPERIMENTAL
Intervention: Clarithromycin 250 mg bid for 5-14 days
Number of subjects: 440
Study 8340194 — intervention group
Group type: COMPARATOR
Intervention: Cefadroxil 500 mg bid for 5-14 days
Number of subjects: 440
Study 8340194 — intervention group
Group type: EXPERIMENTAL
Intervention: Clarithromycin 250 mg qid for ≤ 14 days
Number of subjects: 440
Study 8340194 — intervention group
Group type: COMPARATOR
Intervention: Erythromycin 250 mg qid for ≤ 14 days
Number of subjects: 440
Study 3552457 — intervention group
Group type: EXPERIMENTAL
Intervention: Aqueous lignocaine (5%) spray
Number of subjects: 103
Study 3552457 — intervention group
Group type: COMPARATOR
Intervention: Alcoholic lignocaine (5%) spray
Number of subjects: 103
Study 3552457 — intervention group
Group type: EXPERIMENTAL
Intervention: Mefenamic acid (500 mg)
Number of subjects: 103
Study 3552457 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 103
Study 31197508 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance training plus photobiomodulation (PBMG)
Number of subjects: 34
Study 31197508 — intervention group
Group type: COMPARATOR
Intervention: Resistance training (RTG)
Number of subjects: 34
Study 27151073 — intervention group
Group type: EXPERIMENTAL
Intervention: Body psychotherapy (20 sessions)
Number of subjects: 275
Study 27151073 — intervention group
Group type: COMPARATOR
Intervention: Pilates (active control)
Number of subjects: 275
Study 24721893 — intervention group
Group type: EXPERIMENTAL
Intervention: Pravastatin
Number of subjects: 110
Study 24721893 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 110
Study 22935133 — intervention group
Group type: EXPERIMENTAL
Intervention: Pelican intervention in primary care
Number of subjects: 270
Study 22935133 — intervention group
Group type: EXPERIMENTAL
Intervention: Pelican intervention in specialized care
Number of subjects: 270
Study 20308602 — intervention group
Group type: EXPERIMENTAL
Intervention: PIRR (Peg‐IFN‐alpha + RBV + RTX)
Number of subjects: 37
Study 20308602 — intervention group
Group type: COMPARATOR
Intervention: Peg‐IFN‐alpha/RBV
Number of subjects: 37
Study 18362485 — intervention group
Group type: EXPERIMENTAL
Intervention: Levofloxacin (n = 26)
Number of subjects: 81
Study 18362485 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxazosin (n = 26)
Number of subjects: 81
Study 18362485 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy (n = 29)
Number of subjects: 81
Study 15948790 — intervention group
Group type: EXPERIMENTAL
Intervention: Sildenafil 100 mg
Number of subjects: 20
Study 15948790 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 12911202 — intervention group
Group type: EXPERIMENTAL
Intervention: Trachlight (group T)
Number of subjects: 26
Study 12911202 — intervention group
Group type: COMPARATOR
Intervention: Macintosh laryngoscope (group L)
Number of subjects: 26
Study 10571611 — intervention group
Group type: EXPERIMENTAL
Intervention: Double dose of pantoprazole (2 x 40 mg, Group 2PCA)
Number of subjects: 192
Study 10571611 — intervention group
Group type: COMPARATOR
Intervention: Single dose of pantoprazole (40 mg, Group 1PCA)
Number of subjects: 192
Study 10571611 — intervention group
Group type: EXPERIMENTAL
Intervention: Both regimens (double and single dose of pantoprazole)
Number of subjects: 192
Study 8916062 — intervention group
Group type: EXPERIMENTAL
Intervention: Laser flowmeter (LFM) monitoring during craniotomy
Number of subjects: 31
Study 8916062 — intervention group
Group type: COMPARATOR
Intervention: Control-CBF values
Number of subjects: 31
Study 8916062 — intervention group
Group type: EXPERIMENTAL
Intervention: Laser flowmeter (LFM) monitoring
Number of subjects: 31
Study 1925193 — intervention group
Group type: EXPERIMENTAL
Intervention: Fixed triple combination (0.05 mg reserpine, 2.5 mg clopamide, 0.4 mg dihydroergocristine)
Number of subjects: 34
Study 1925193 — intervention group
Group type: COMPARATOR
Intervention: Fixed double combination (0.05 mg reserpine, 2.5 mg clopamide)
Number of subjects: 34
Study 1925193 — intervention group
Group type: EXPERIMENTAL
Intervention: Fixed triple combination
Number of subjects: 34
Study 1925193 — intervention group
Group type: COMPARATOR
Intervention: Fixed double combination
Number of subjects: 34
Study 31798029 — intervention group
Group type: EXPERIMENTAL
Intervention: sEMG measurement of spinal extensors activity
Number of subjects: 50
Study 31798029 — intervention group
Group type: EXPERIMENTAL
Intervention: Body position during work
Number of subjects: 50
Study 28027794 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraperitoneal vancomycin, 1g, every 5 days plus oral moxifloxacin, 400mg, every day
Number of subjects: 80
Study 28027794 — intervention group
Group type: COMPARATOR
Intervention: Intraperitoneal vancomycin, 1g, every 5 days plus intraperitoneal ceftazidime, 1g, every day
Number of subjects: 80
Study 25863661 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose recombinant human erythropoietin (rhEpo) 3000 U/kg body weight
Number of subjects: 443
Study 25863661 — intervention group
Group type: COMPARATOR
Intervention: NaCl 0.9% (control)
Number of subjects: 443
Study 25863661 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose recombinant human erythropoietin (rhEpo)
Number of subjects: 443
Study 23547787 — intervention group
Group type: EXPERIMENTAL
Intervention: Test-informed condition (participants informed that boundary memory would be tested)
Number of subjects: 0
Study 23547787 — intervention group
Group type: COMPARATOR
Intervention: Non test-informed condition (participants not informed about boundary memory testing)
Number of subjects: 0
Study 21335616 — intervention group
Group type: EXPERIMENTAL
Intervention: PONI (modular protocol for on-site, nurse-administered intervention)
Number of subjects: 163
Study 21335616 — intervention group
Group type: COMPARATOR
Intervention: EUC (enhanced usual care)
Number of subjects: 163
Study 21335616 — intervention group
Group type: EXPERIMENTAL
Intervention: PONI
Number of subjects: 163
Study 21335616 — intervention group
Group type: COMPARATOR
Intervention: EUC
Number of subjects: 163
Study 19519256 — intervention group
Group type: EXPERIMENTAL
Intervention: Guanfacine extended release (GXR)
Number of subjects: 202
Study 17530098 — intervention group
Group type: EXPERIMENTAL
Intervention: Off-pump technique
Number of subjects: 45
Study 17530098 — intervention group
Group type: COMPARATOR
Intervention: Conventional technique
Number of subjects: 45
Study 17530098 — intervention group
Group type: EXPERIMENTAL
Intervention: On-pump beating-heart technique
Number of subjects: 45
Study 15385352 — intervention group
Group type: EXPERIMENTAL
Intervention: Electro-acupoint stimulation
Number of subjects: 0
Study 15385352 — intervention group
Group type: EXPERIMENTAL
Intervention: Ondansetron 4 mg IV
Number of subjects: 0
Study 15385352 — intervention group
Group type: COMPARATOR
Intervention: Placebo (sham control)
Number of subjects: 0
Study 11293559 — intervention group
Group type: EXPERIMENTAL
Intervention: 100-mg sumatriptan tablets
Number of subjects: 231
Study 11293559 — intervention group
Group type: COMPARATOR
Intervention: 50-mg sumatriptan tablets
Number of subjects: 231
Study 9674377 — intervention group
Group type: EXPERIMENTAL
Intervention: Dynamometer testing for peak force (PF) in the sagittal plane
Number of subjects: 13